On the 1st of December 2025, we assembled to review the latest updates to the JFDA Bioequivalence Guidelines and the new ICH M13 Guidelines.
We extend our sincere appreciation to our colleagues at the JFDA for presenting the key updates on the new requirements and the implementation of M13A, and for their continued dedication under the leadership of H.E. Dr. Rana Obeidat, Director General of the JFDA.
Our gratitude is also extended to the esteemed speakers:
We greatly appreciate their insightful presentations and valuable contributions, which were essential to the success of the workshop.
The event was further enriched by the participation of distinguished professionals from the JFDA, respected members of the DOA, and representatives from various multinational and local pharmaceutical companies and distributors. Their active engagement and thoughtful discussions significantly enhanced the quality and outcomes of this important gathering.
Join our community of 3 million people and get updated every week We have a lot more just for you! Lets join us now
Whether you’re a member, partner, or simply interested in learning more about DOA, we would love to hear from you!
Reach out to us via Doaregulatory@gmail.com
For a more personal contact, we are happy to hear from you via: +962 7 9578 0250
DOA proudly represents 19 leading pharmaceutical importers and distributors, including the founders of Jordan’s pharmaceutical sector. Our members uphold international standards of quality and service
+962 79 578 0250
Doaregulatory@gmail.com
Wazzan Building, Saleh Smadi Street 15,
Sweifeyeh, Amman Jordan